Effects of an actual insulin injection demonstration on insulin acceptance among patients with T2DM: a pragmatic randomized controlled trial

1. NDISANG JF., VANNACCI A., RASTOGI S. Insulin resistance, type 1 and type 2 diabetes, and related complications 2017. J Diabetes Res. 2017; 2017:1478294.10.1155/2017/1478294Search in Google Scholar

2. TAYLOR R. Insulin resistance and type 2 diabetes. Diabetes. 2012; 61(4):778–9.10.2337/db12-0073Search in Google Scholar

3. NICKERSON HD., DUTTA S. Diabetic complications: current challenges and opportunities. J Cardiovasc Transl Res. 2012; 5(4):375–9.10.1007/s12265-012-9388-1Search in Google Scholar

4. PAPATHEODOROU K., BANACH M., BEKIARI E., RIZZO M., EDMONDS M. Complications of diabetes 2017. J Diabetes Res. 2018; 2018:3086167.10.1155/2018/3086167Search in Google Scholar

5. SHAN PF., LI Q., KHAMAISI M., QIANG GF. Type 2 Diabetes mellitus and macrovascular complications. Int J Endocrinol. 2017; 2017:4301461.10.1155/2017/4301461Search in Google Scholar

6. JING X., CHEN J., DONG Y., HAN D., ZHAO H., WANG X., et al. Related factors of quality of life of type 2 diabetes patients: a systematic review and meta-analysis. Health Qual Life Outcomes. 2018; 16(1):189.10.1186/s12955-018-1021-9Search in Google Scholar

7. TRIKKALINOU A., PAPAZAFIROPOULOU AK., MELIDONIS A. Type 2 diabetes and quality of life. World J Diabetes. 2017; 8(4):120–9.10.4239/wjd.v8.i4.120Search in Google Scholar

8. WOU C., UNWIN N., HUANG Y., ROGLIC G. Implications of the growing burden of diabetes for premature cardiovascular disease mortality and the attainment of the Sustainable Development Goal target 3.4. Cardiovasc Diagn Ther. 2019; 9(2):140–9.10.21037/cdt.2018.09.04Search in Google Scholar

9. GBD 2017 DISEASE AND INJURY INCIDENCE AND PREVALENCE COLLABORATORS. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789–858.10.1016/S0140-6736(18)32279-7Search in Google Scholar

10. INTERNATIONAL DIABETES FEDERATION. IDF Diabetes Atlas. 9 ed, 2019.Search in Google Scholar

11. GBD 2017 CAUSES OF DEATH COLLABORATORS. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736–88.10.1016/S0140-6736(18)32203-7Search in Google Scholar

12. KHAN MAB., HASHIM MJ., KING JK., GOVENDER RD., MUSTAFA H., Al KAABI J. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020; 10(1):107–11.10.2991/jegh.k.191028.001Search in Google Scholar

13. SEURING T., ARCHANGELIDI O., SUHRCKE M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015; 33(8):811–31.10.1007/s40273-015-0268-9451963325787932Search in Google Scholar

14. MARIN-PENALVER JJ., MARTIN-TIMON I., SEVILLANO-COLLANTES C., DEL CANIZO-GOMEZ FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016; 7(17):354–95.10.4239/wjd.v7.i17.354502700227660695Search in Google Scholar

15. INZUCCHI SE., BERGENSTAL RM., BUSE JB., DIAMANT M., FERRANNINI E., NAUCK M., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1):140–9.10.2337/dc14-244125538310Search in Google Scholar

16. CHAUDHURY A., DUVOOR C., REDDY DENDI VS., KRALETI S., CHADA A., RAVILLA R., et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). 2017; 8:6.10.3389/fendo.2017.00006525606528167928Search in Google Scholar

17. TRAN L., ZIELINSKI A., ROACH AH., JENDE JA., HOUSEHOLDER AM., COLE EE., et al. Pharmacologic treatment of type 2 diabetes: oral medications. Ann Pharmacother. 2015; 49(5):540–56.10.1177/106002801455828925667196Search in Google Scholar

18. LEE BW., KIM JH., KO SH., HUR KY., KIM NH., RHEE SY., et al. Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017. Diabetes Metab J. 2017; 41(5):367–73.10.4093/dmj.2017.41.5.367566367529086534Search in Google Scholar

19. LARKIN ME., CAPASSO VA., CHEN CL., MAHONEY EK., HAZARD B., CAGLIERO E., et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008; 34(3):511–7.10.1177/014572170831786918535324Search in Google Scholar

20. POLONSKY WH., FISHER L., GUZMAN S., VILLA-CABALLERO L., EDELMAN SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005; 28(10):2543–5.10.2337/diacare.28.10.254316186296Search in Google Scholar

21. SONG Y., KU BJ., CHO J., JUN Y., KIM B., NAM S. The prevalence of insulin refusal and psychological insulin resistance among Korean patients with type 2 diabetes mellitus. Ann Transl Med. 2019; 7(23):760.10.21037/atm.2019.11.77698997432042776Search in Google Scholar

22. TAN WL., ASAHAR SF., HARUN NL. Insulin therapy refusal among type II diabetes mellitus patients in Kubang Pasu district, the state of Kedah, Malaysia. Singapore Med J. 2015; 56(4):224–7.10.11622/smedj.2014170441510325532511Search in Google Scholar

23. WOUDENBERG YJ., LUCAS C., LATOUR C., SCHOLTE OP REIMER WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012; 29(6):796–802.10.1111/j.1464-5491.2011.03552.x22150962Search in Google Scholar

24. NG CJ., LAI PS., LEE YK., AZMI SA., TEO CH. Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review. Int J Clin Pract. 2015; 69(10):1050–70.10.1111/ijcp.1269126147376Search in Google Scholar

25. NGAMJARUS C., CHONGSUVIVATWONG V., McNEIL E. n4Studies: sample size calculation for an epidemiological study on a smart device. Siriraj Med J. 2016; 68:160–70.Search in Google Scholar

26. ABU HASSAN H., TOHID H., MOHD AMIN R., LONG BIDIN MB., MUTHUPALANIAPPEN L., OMAR K. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam Pract. 2013; 14:164.10.1186/1471-2296-14-164423161124164794Search in Google Scholar

27. BANERJEE A., CHITNIS UB., JADHAV SL., BHAWALKER JS., CHAUDHURY S. Hypothesis testing, type I and type II errors. Ind Psychiatry J. 2009; 18(2):127–31.10.4103/0972-6748.62274299619821180491Search in Google Scholar

28. BIN RSHEED A., CHENOWETH I. Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome. World J Diabetes. 2017; 8(1):28–39.10.4239/wjd.v8.i1.28523781528138362Search in Google Scholar

29. KABADI UM. Starting insulin in type 2 diabetes: overcoming barriers to insulin therapy. Int J Diabetes Dev Ctries. 2008; 28(2):65–8.10.4103/0973-3930.43102277200619902051Search in Google Scholar

30. RUSSELL-JONES D., POUWER F., KHUNTI K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018; 20(3):488–96.10.1111/dom.13132583693329053215Search in Google Scholar

31. ALLEN NA., ZAGARINS SE., FEINBERG RG., WELCH G.. Treating psychological insulin resistance in type 2 diabetes. J Clin Transl Endocrinol. 2016; 7:1–6.10.1016/j.jcte.2016.11.005Search in Google Scholar

32. KAPOOR U., RAMASAMY G., SELVARAJ K., SAHOO JP., KAR SS. Does one-to-one demonstration with insulin pads by health-care providers improves the insulin administration techniques among diabetic patients of a tertiary care teaching hospital in South India? Indian J Endocrinol Metab. 2016; 20(6):767–71.10.4103/2230-8210.192904510555827867877Search in Google Scholar

33. DAVIDSON MB. Insulin therapy: a personal approach. Clin Diabetes. 2015; 33(3):123–35.10.2337/diaclin.33.3.123450394126203205Search in Google Scholar

34. McCAMBRIDGE J., WITTON J., ELBOURNE DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014; 67(3):267–77.10.1016/j.jclinepi.2013.08.015396924724275499Search in Google Scholar

35. RAKEL RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Adv Therapy. 2009; 26(9):838–46.10.1007/s12325-009-0061-219768641Search in Google Scholar

36. DAL-RE R., JANIAUD P., IOANNIDIS JPA. Real-world evidence: how pragmatic are randomized controlled trials labeled as pragmatic? BMC Med. 2018; 16(1):49.10.1186/s12916-018-1038-2588339729615035Search in Google Scholar

37. ZWARENSTEIN M., TREWEEK S., GAGNIER JJ., ALTMAN DG., TUNIS S., HAYNES B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008; 337:a2390.10.1136/bmj.a2390326684419001484Search in Google Scholar